# Tyra Biosciences, Inc. (TYRA) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_befc11f746ce38306dd0 · retrieved 2026-08-11T16:01:54.720Z

## Overview
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, with its lead candidate oral dabogratinib in Phase 2 development for urologic cancers and skeletal dysplasias.

Tyra Biosciences, Inc. amended its at-the-market (ATM) sales agreement with TD Securities (USA) LLC in August 2026. Under the amended agreement, the company may sell an additional $250.0 million of shares of its common stock from time to time in at-the-market offerings, subject to the terms of an effective registration statement.

## Terms
- Counterparty: TD Securities (USA) LLC · Deal value: $250.0M · Consideration: stock

## Key dates
- Announced 2026-08-04

## Timeline
- 2026-08-04 · 8-K (0001193125-26-332752): 8-K - Tyra Biosciences, Inc. — *Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, with its lead candidate oral dabogratinib in Phase 2 development for urologic cancers and skeletal dysplasias.* Tyra Biosciences, Inc. amended its at-the-market (ATM) sales agreement with TD Securities (USA) LLC in August 2026. Under the amended agreement, the company may sell an additional $250.0 million of shares of its common stock from time to time in at-the-market offerings, subject to the terms of an effective registration statement.
  https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-332752.txt

## Citations
- 0001193125-26-332752 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526332752